Q-omics provides the consensus-scored CNGB3 profile across patient tissues and cancer cell-line models. CNGB3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CNGB3 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, CNGB3 RNA expression shows 14,770 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, BLCA, and ACC as cancer lineages where CNGB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNGB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNGB3 survival associations across molecular data types. CNGB3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNGB3 RNA expression–survival associations across cancer types. High CNGB3 expression shows unfavorable associations in STAD, KIRC, KIRP, COAD and UVM, but favorable associations in BRCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for CNGB3 RNA expression.
This table summarizes CNGB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CNGB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNGB3 shows lower tumor expression in UCEC and higher tumor expression in BLCA, HNSC, LUSC, KICH and LUAD. The BLCA box plot shows higher CNGB3 RNA expression in tumor versus normal tissue (log2 FC = +0.532, t-test p < 0.001).
This table shows molecular features associated with CNGB3 in patient tissues and cancer cell lines. In patient samples, CNGB3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CNGB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
